Macular Telangiectasia Type 2: A Comprehensive Review

被引：11
|
作者：
Kedarisetti, Kiran Chandra [1 ]
Narayanan, Raja [1 ,2 ,6 ]
Stewart, Michael W. [3 ]
Gurram, Nikitha Reddy [1 ]
Khanani, Arshad M. [4 ,5 ]
机构：
[1] LV Prasad Eye Inst, Anant Bajaj Retina Inst, Hyderabad, Telangana, India
[2] Publ Hlth & Econ Res Ctr IHOPE, Indian Hlth Outcomes, Hyderabad, Telangana, India
[3] Mayo Clin, Dept Ophthalmol, Jacksonville, FL USA
[4] Sierra Eye Associates, Dept Clin Res, Reno, NV USA
[5] Univ Nevada, Dept Ophthalmol, Reno, NV USA
[6] L V Prasad Eye Inst, Anant Bajaj Retina Inst, Hyderabad, Telangana, India
来源：
CLINICAL OPHTHALMOLOGY | 2022年 / 16卷
关键词：
macular telangiectasia type 2; MacTel; CNTF; ciliary neurotrophic factor; OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL NEOVASCULARIZATION SECONDARY; JUXTAFOVEOLAR RETINAL TELANGIECTASIS; INTRAVITREAL BEVACIZUMAB THERAPY; GRID LASER PHOTOCOAGULATION; GROWTH-FACTOR THERAPY; PHOTODYNAMIC THERAPY; SUBFOVEAL NEOVASCULARIZATION; FUNDUS AUTOFLUORESCENCE; FLUORESCEIN-ANGIOGRAPHY;
D O I：
10.2147/OPTH.S373538
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
Macular telangiectasia Type 2 (MacTel) is a gradually progressive disease that affects the quality of life by impairing both distant and near vision. It had previously been considered a vascular condition, but recent evidence suggests a neurodegenerative etiology, with primary involvement of Muller cells. Retinal pigment epithelium (RPE) hyperplasia and subretinal neovascularization (SNV) are responsible for most of the vision loss in advanced cases. Neurotrophic factors in the non-proliferative phase and intravitreal anti-Vascular Endothelial growth factor (VEGF) in the proliferative phase have shown to retard the progression of the disease. This review will discuss the pathophysiology, clinical features, important diagnostic imaging studies and available treatment options for MacTel.
引用
收藏
页码：3297 / 3309
页数：13
相关论文
共 50 条
  • [41] EFFICACY OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN SUBRETINAL NEOVASCULARIZATION SECONDARY TO MACULAR TELANGIECTASIA TYPE 2
    Narayanan, Raja
    Chhablani, Jay
    Sinha, Manish
    Dave, Vivek
    Tyagi, Mudit
    Pappuru, Rajeev R.
    Kuppermann, Baruch D.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2012, 32 (10): : 2001 - 2005
  • [42] Type II idiopathic macular telangiectasia and soft confluent drusen
    Querques, Giuseppe
    Coscas, Gabriel
    Soubrane, Gisele
    Souied, Eric H.
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2010, 20 (02) : 466 - 468
  • [43] Long-term course in type 2 idiopathic macular telangiectasia
    Meyer-ter-Vehn, Tobias
    Herzog, Sina
    Schargus, Marc
    Goebel, Winfried
    Guthoff, Rainer
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2013, 251 (11) : 2513 - 2520
  • [44] Macular full-thickness and lamellar holes in association with type 2 idiopathic macular telangiectasia
    Issa, P. Charbel
    Scholl, H. P. N.
    Gaudric, A.
    Massin, P.
    Kreiger, A. E.
    Schwartz, S.
    Holz, F. G.
    EYE, 2009, 23 (02) : 435 - 441
  • [45] CONCURRENT IDIOPATHIC MACULAR TELANGIECTASIA TYPE 2 AND CENTRAL SEROUS CHORIORETINOPATHY
    Matet, Alexandre
    Yzer, Suzanne
    Chew, Emily Y.
    Daruich, Alejandra
    Behar-Cohen, Francine
    Spaide, Richard F.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2018, 38 : S67 - S78
  • [46] A case of macular telangiectasia type 2 with bilateral macular holes: Imaging features and surgical management
    Usami, Yuta
    Wahyuningsih, Eka Rahmawati
    Nakano, Kana
    Kuwayama, Satoshi
    Ogura, Shuntaro
    Kimura, Masayo
    Kato, Aki
    Hirano, Yoshio
    Ogura, Yuichiro
    Yasukawa, Tsutomu
    MEDICINE, 2025, 104 (12) : e41847
  • [47] The preproliferative stage in type 2 macular telangiectasia (MacTel type 2)
    Venkatesh, Ramesh
    Reddy, Nikitha Gurram
    Mishra, Pranjal
    Pereira, Arpitha
    Mutalik, Deepashri
    Agrawal, Sameeksha
    Bhatt, Abhishek
    Yadav, Naresh Kumar
    Chhablani, Jay
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2022, 260 (01) : 121 - 132
  • [48] Monthly Ranibizumab for Nonproliferative Macular Telangiectasia Type 2: A 12-Month Prospective Study
    Issa, Peter Charbel
    Finger, Robert P.
    Kruse, Kathrin
    Baumueller, Soenke
    Scholl, Hendrik P. N.
    Holz, Frank G.
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2011, 151 (05) : 876 - 886
  • [49] Retinal Ganglion Cells Thinning in Eyes With Nonproliferative Idiopathic Macular Telangiectasia Type 2A
    Chhablani, Jay
    Rao, Harsha B.
    Begum, Viquar Unnisa
    Jonnadulla, Ganesh Babu
    Goud, Ashwin
    Barteselli, Giulio
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (02) : 1416 - 1422
  • [50] The Prevalence of Macular Telangiectasia Type 2 in the Beaver Dam Eye Study
    Klein, Ronald
    Blodi, Barbara A.
    Meuer, Stacy M.
    Myers, Chelsea E.
    Chew, Emily Y.
    Klein, Barbara E. K.
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2010, 150 (01) : 55 - 62
12345